| DARTIGEAS, Caroline |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
NCT03766763: Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage a |
|
|
| Active, not recruiting | 2 | 82 | Europe | Venetoclax | French Innovative Leukemia Organisation | Chronic Lymphoid Leukemia | 01/22 | 04/30 | | |
GLORIFY, NCT06186648: Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome |
|
|
| Recruiting | 2 | 40 | Europe | Glofitamab + Obinutuzumab | French Innovative Leukemia Organisation, Hoffmann-La Roche | Richter Syndrome | 03/26 | 03/27 | | |
STAIR, NCT04963946: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 2 | 160 | Europe | Stop ACA, ACA Continuation | French Innovative Leukemia Organisation | Untreated Chronic Lymphocytic Leukemia | 01/26 | 08/28 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
LAMSA2020, NCT04968015: Venetoclax + Cytarabine Versus Idarubicin + Cytarabine : Efficacity Assessment as Post-remission Therapy to Elderly Patients With Acute Myeloid Leukemia in First Remission |
|
|
| Active, not recruiting | 2 | 134 | Europe | Cytarabine-Venetoclax Association, Cytarabine-Idarubicin Association | French Innovative Leukemia Organisation | Acute Myeloid Leukemia | 08/25 | 01/29 | | |
COVID19_LLC-MW, NCT04391946: Observatory of Patients With Chronic Lymphocytic Leukemia / Lymphocytic Lymphoma or Waldenstrom Disease Infected With COVID-19 |
|
|
| Completed | N/A | 162 | Europe | Data registry | French Innovative Leukemia Organisation, Institut de cancérologie Strasbourg Europe | Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma or Waldenstrom Disease | 03/22 | 03/23 | | |
THEMIS, NCT05350826: Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic Leukemia |
|
|
| Recruiting | N/A | 450 | Europe | Ambulatory medical assistance | University Hospital, Toulouse | Chronic Lymphoid Leukemia | 07/25 | 07/25 | | |
FOLLOW, NCT05590702: French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings |
|
|
| Recruiting | N/A | 1000 | Europe | First line therapy | French Innovative Leukemia Organisation, AbbVie, AstraZeneca, BeiGene, Janssen-Cilag Ltd. | CLL/SLL | 11/25 | 12/32 | | |
| VILLATE, Alban |
| Completed | 2 | 42 | Europe | CPX-351 | French Innovative Leukemia Organisation, Acute Leukemia French Association, French Intergroup of Myeloproliferative syndromes | Acute Myeloid Leukemia, Myeloproliferative Syndrome | 10/23 | 12/23 | | |
| Recruiting | 2 | 50 | Europe | Gemtuzumab ozogamicine - Cytarabine - Gilteritinib, Mylotarg - Aracytine - Xospata | Centre Antoine Lacassagne, Acute Leukemia French Association | AML | 03/27 | 03/27 | | |
ALFA2101, NCT05260528: CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics |
|
|
| Recruiting | 2 | 210 | Europe | Cytarabine and Idarubicin, CPX-315 | Centre Hospitalier Universitaire de Nice, Jazz Pharmaceuticals, Acute Leukemia French Association | Acute Myeloid Leukemia | 10/27 | 10/27 | | |
VENAZA, NCT06263387: Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine |
|
|
| Recruiting | N/A | 230 | Europe | | French Innovative Leukemia Organisation, Acute Leukemia French Association | AML, Adult | 12/24 | 03/25 | | |
ALHERT, NCT06409767: Impact of an Early Warning System on the Prognosis of Patients With Hematological Malignancies Receiving Intensive Chemotherapy With or Without Hematopoietic Cell Transplantation. |
|
|
| Not yet recruiting | N/A | 2224 | Europe | Real-time calculation of the NEWS with ICU admission if NEWS ≥ 7. | University Hospital, Angers | Leukemia, Lymphoma, Multiple Myeloma | 10/27 | 01/28 | | |
